TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated a statistically significant and clinically meaningful benefit across multiple measures of pain and in a post-hoc analysis ...
Eli Lilly (LLY) announced topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral glucagon-like peptide-1 receptor agonist, in 3,127 adults with obesity, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback